Announced Wed, 24 Jun · 08:33 IST
Biocon partner Duopharma wins MYR 225M insulin tenders in Malaysia
Compliance View source PDF
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.7%1-day move
₹423.30
prior close
₹426.45
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+0.1-0.2-0.6-1.7-2.1-1.1-1.3-1.0+0.2+4.4+2.4——
Up moveDown movePending
AI summary
Biocon's partner Duopharma Biotech secured Malaysian Ministry of Health insulin contracts worth over MYR 225 million. Includes a 3-year human insulin deal of MYR 155.27M and 2-year deals for insulin glargine (MYR 18M) and insulin aspart (MYR 52.5M). Biocon's Malaysia subsidiary will manufacture and supply these insulins. The partners have delivered over 120 million insulin cartridges to 450,000+ patients in Malaysia over the past decade.
Likely market impact
Positive - multi-year contracts strengthen insulin revenue visibility and Biocon's Malaysian market presence